{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:03:35Z","timestamp":1781561015615,"version":"3.54.5"},"reference-count":147,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.prp.2024.155589","type":"journal-article","created":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T14:09:36Z","timestamp":1725804576000},"page":"155589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Molecular targets in SARS-CoV-2 infection: An update on repurposed drug candidates"],"prefix":"10.1016","volume":"263","author":[{"given":"Dibachehr","family":"Rahmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameneh","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12575-020-00129-1","article-title":"Potential drugs and remedies for the treatment of COVID-19: a critical review","volume":"22","author":"Barati","year":"2020","journal-title":"Biol. Proced. Online"},{"issue":"17","key":"10.1016\/j.prp.2024.155589_bib2","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.4155\/fmc-2020-0147","article-title":"Tackling SARS-CoV-2: proposed targets and repurposed drugs","volume":"12","author":"Joshi","year":"2020","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.prp.2024.155589_bib3","article-title":"Potential drug options for treatment of COVID-19: a review","volume":"4","author":"Kebede","year":"2020","journal-title":"World Health"},{"issue":"8","key":"10.1016\/j.prp.2024.155589_bib4","article-title":"Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells","volume":"1","author":"Carpinteiro","year":"2020","journal-title":"Cell Rep. Med."},{"issue":"3","key":"10.1016\/j.prp.2024.155589_bib5","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jmii.2020.03.034","article-title":"Treatment options for COVID-19: the reality and challenges","volume":"53","author":"Jean","year":"2020","journal-title":"J. Microbiol., Immunol. Infect."},{"issue":"21","key":"10.1016\/j.prp.2024.155589_bib6","doi-asserted-by":"crossref","first-page":"12359","DOI":"10.1021\/acs.jmedchem.0c00606","article-title":"COVID-19: drug targets and potential treatments","volume":"63","author":"Gil","year":"2020","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.prp.2024.155589_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3110","article-title":"Computational drug repurposing study of the RNA binding domain of SARS-CoV-2 nucleocapsid protein with antiviral agents","volume":"37","author":"Tatar","year":"2021","journal-title":"Biotechnol. Prog."},{"issue":"2","key":"10.1016\/j.prp.2024.155589_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"cell"},{"issue":"8","key":"10.1016\/j.prp.2024.155589_bib9","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1080\/07391102.2020.1754293","article-title":"A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin","volume":"39","author":"Hasan","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.prp.2024.155589_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaa113","article-title":"The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much?","author":"Essig","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"10.1016\/j.prp.2024.155589_bib11","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.5114\/aoms\/152467","article-title":"Perspective: repurposed drugs for COVID-19","volume":"18","author":"Na-Bangchang","year":"2022","journal-title":"Arch. Med. Sci."},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)","volume":"14","author":"Lu","year":"2020","journal-title":"Biosci. Trends"},{"issue":"6","key":"10.1016\/j.prp.2024.155589_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3390\/vaccines9060557","article-title":"The relevance of monoclonal antibodies in the treatment of COVID-19","volume":"9","author":"Torrente-L\u00f3pez","year":"2021","journal-title":"Vaccines"},{"issue":"6","key":"10.1016\/j.prp.2024.155589_bib14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"24","key":"10.1016\/j.prp.2024.155589_bib15","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.prp.2024.155589_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2021.102329","article-title":"Molnupiravir in COVID-19: a systematic review of literature","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab. Syndr.: Clin. Res. Rev."},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib17","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19\uff1a a meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann. Med."},{"issue":"just-accepted","key":"10.1016\/j.prp.2024.155589_bib18","first-page":"1","article-title":"Identification of chymotrypsin-like protease inhibitors of SARS-Cov-2 via integrated computational approach","author":"Khan","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"7798","key":"10.1016\/j.prp.2024.155589_bib19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12038-020-00067-w","article-title":"Drug targets for COVID-19 therapeutics: ongoing global efforts","volume":"45","author":"Saxena","year":"2020","journal-title":"J. Biosci."},{"key":"10.1016\/j.prp.2024.155589_bib21","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.0c00606","article-title":"COVID-19: Drug targets and potential treatments","author":"Gil","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.prp.2024.155589_bib22","first-page":"8","article-title":"The molecular docking study of potential drug candidates showing anti-COVID-19 activity by exploring of therapeutic targets of SARS-CoV-2","volume":"5","author":"Narkhede","year":"2020","journal-title":"screening"},{"key":"10.1016\/j.prp.2024.155589_bib23","doi-asserted-by":"crossref","unstructured":"Walls A.C., Park Y.-J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020.","DOI":"10.1101\/2020.02.19.956581"},{"issue":"10","key":"10.1016\/j.prp.2024.155589_bib24","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1002\/ptr.7151","article-title":"Natural products and phytochemicals as potential anti-SARS-CoV-2 drugs","volume":"35","author":"Merarchi","year":"2021","journal-title":"Phytother. Res."},{"key":"10.1016\/j.prp.2024.155589_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/1348-0421.12754","article-title":"Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs","volume":"64","author":"Sekimukai","year":"2020","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.prp.2024.155589_bib27","unstructured":"Zhang G., Pomplun S., Loftis A.R., Loas A., Pentelute B.L. The first-in-class peptide binder to the SARS-CoV-2 spike protein. bioRxiv. 2020."},{"key":"10.1016\/j.prp.2024.155589_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173720","article-title":"Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19","volume":"890","author":"Toor","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.prp.2024.155589_bib29","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2174\/1570180818666210427095203","article-title":"Design, synthesis, and in silico studies of novel N-(2-aminophenyl)-2, 3-diphenylquinoxaline-6-sulfonamide derivatives targeting receptor-binding domain (RBD) of SARS-CoV-2 spike glycoprotein and their evaluation as antimicrobial and antimalarial agents","volume":"18","author":"Siddiqui","year":"2021","journal-title":"Lett. Drug Des. Discov."},{"issue":"4","key":"10.1016\/j.prp.2024.155589_bib30","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.prp.2024.155589_bib31","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1080\/07391102.2020.1772885","article-title":"Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening","volume":"39","author":"de Oliveira","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.prp.2024.155589_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173836","article-title":"Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations","volume":"894","author":"Padhi","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.prp.2024.155589_bib33","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1002\/jmv.27820","article-title":"Comprehensive role of SARS-CoV-2 spike glycoprotein in regulating host signaling pathway","volume":"94","author":"Banerjee","year":"2022","journal-title":"J. Med. Virol."},{"issue":"9","key":"10.1016\/j.prp.2024.155589_bib34","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","article-title":"N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2","volume":"184","author":"McCallum","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.prp.2024.155589_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153286","article-title":"Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review","volume":"85","author":"Mhatre","year":"2021","journal-title":"Phytomedicine"},{"issue":"18","key":"10.1016\/j.prp.2024.155589_bib36","doi-asserted-by":"crossref","first-page":"10279","DOI":"10.1002\/anie.202100316","article-title":"A SARS-CoV-2 spike binding DNA Aptamer that inhibits Pseudovirus infection by an RBD-independent mechanism","volume":"60","author":"Schmitz","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"issue":"9","key":"10.1016\/j.prp.2024.155589_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009885","article-title":"Current status of therapeutic monoclonal antibodies against SARS-CoV-2","volume":"17","author":"Kumar","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.prp.2024.155589_bib38","first-page":"49","article-title":"for Bamlanivimab and Etesevimab for COVID-19","volume":"63","author":"Orders","year":"2021","journal-title":"Med Lett. Drugs Ther."},{"issue":"1614","key":"10.1016\/j.prp.2024.155589_bib39","first-page":"201","article-title":"for Casirivimab and Imdevimab for COVID-19","volume":"62","author":"Orders","year":"2020","journal-title":"Med Lett. Drugs Ther."},{"key":"10.1016\/j.prp.2024.155589_bib40","doi-asserted-by":"crossref","unstructured":"Dong J., Zost S.J., Greaney A.J., Starr T.N., Dingens A.S., Chen E.C., et al. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. BioRxiv. 2021:2021.01. 27.428529.","DOI":"10.1101\/2021.01.27.428529"},{"issue":"5","key":"10.1016\/j.prp.2024.155589_bib41","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10787-019-00607-3","article-title":"Curcumin: a modulator of inflammatory signaling pathways in the immune system","volume":"27","author":"Kahkhaie","year":"2019","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.prp.2024.155589_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jnutbio.2018.12.005","article-title":"Macrophage plasticity, polarization and function in response to curcumin, a diet-derived polyphenol, as an immunomodulatory agent","volume":"66","author":"Mohammadi","year":"2019","journal-title":"J. Nutr. Biochem"},{"key":"10.1016\/j.prp.2024.155589_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctim.2020.102322","article-title":"Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial","volume":"49","author":"Saberi-Karimian","year":"2020","journal-title":"Complement Ther. Med"},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaim.2020.05.009","article-title":"In silico computational screening of Kabasura Kudineer-official Siddha formulation and JACOM against SARS-CoV-2 spike protein","volume":"13","author":"Kiran","year":"2022","journal-title":"J. Ayurveda Integr. Med."},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib45","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/ijp.IJP_115_20","article-title":"Drug targets for corona virus: A systematic review","volume":"52","author":"Prajapat","year":"2020","journal-title":"Indian J. Pharmacol."},{"issue":"4","key":"10.1016\/j.prp.2024.155589_bib46","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.drudis.2015.11.015","article-title":"Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein","volume":"21","author":"Chang","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.prp.2024.155589_bib47","doi-asserted-by":"crossref","unstructured":"Kang S., Yang M., Hong Z., Zhang L., Huang Z., Chen X., et al. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharmaceutica Sinica B. 2020.","DOI":"10.1101\/2020.03.06.977876"},{"issue":"6","key":"10.1016\/j.prp.2024.155589_bib48","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1021\/jm500089r","article-title":"Structural basis for the identification of the N-terminal domain of coronavirus nucleocapsid protein as an antiviral target","volume":"57","author":"Lin","year":"2014","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.prp.2024.155589_bib49","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/v13061115","article-title":"The SARS-CoV-2 nucleocapsid protein and its role in viral structure, biological functions, and a potential target for drug or vaccine mitigation","volume":"13","author":"Bai","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-019-1182-0","article-title":"Coronavirus envelope protein: current knowledge","volume":"16","author":"Schoeman","year":"2019","journal-title":"Virol. J."},{"key":"10.1016\/j.prp.2024.155589_bib51","first-page":"2020","article-title":"Sars-CoV-2 Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics?","author":"Bianchi","year":"2020","journal-title":"BioMed. Res. Int."},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib52","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ygeno.2020.11.009","article-title":"Repurposed drugs and nutraceuticals targeting envelope protein: A possible therapeutic strategy against COVID-19","volume":"113","author":"Das","year":"2021","journal-title":"Genomics"},{"issue":"10","key":"10.1016\/j.prp.2024.155589_bib53","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1021\/acs.jctc.1c00359","article-title":"Computational study on the function of palmitoylation on the envelope protein in SARS-CoV-2","volume":"17","author":"Sun","year":"2021","journal-title":"J. Chem. Theory Comput."},{"issue":"7","key":"10.1016\/j.prp.2024.155589_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000511","article-title":"Structure and inhibition of the SARS coronavirus envelope protein ion channel","volume":"5","author":"Pervushin","year":"2009","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.prp.2024.155589_bib55","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3390\/covid2020011","article-title":"A comprehensive review of drug repurposing strategies against known drug targets of COVID-19","volume":"2","author":"Khataniar","year":"2022","journal-title":"Covid"},{"key":"10.1016\/j.prp.2024.155589_bib56","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3389\/fcimb.2021.789180","article-title":"ACE2 Shedding and the Role in COVID-19","volume":"11","author":"Wang","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"9","key":"10.1016\/j.prp.2024.155589_bib57","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.scib.2020.12.005","article-title":"Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2","volume":"66","author":"Gu","year":"2021","journal-title":"Sci. Bull."},{"key":"10.1016\/j.prp.2024.155589_bib58","article-title":"Tackling SARS-CoV-2: proposed targets and repurposed drugs","volume":"0","author":"Joshi","year":"2020","journal-title":"Future Med Chem."},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib59","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01872-15","article-title":"The membrane protein of severe acute respiratory syndrome coronavirus functions as a novel cytosolic pathogen-associated molecular pattern to promote beta interferon induction via a Toll-like-receptor-related TRAF3-independent mechanism","volume":"7","author":"Wang","year":"2016","journal-title":"MBio"},{"key":"10.1016\/j.prp.2024.155589_bib60","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.3389\/fmicb.2020.592908","article-title":"Molecular docking reveals ivermectin and remdesivir as potential repurposed drugs against SARS-CoV-2","volume":"11","author":"Eweas","year":"2021","journal-title":"Front. Microbiol."},{"issue":"6","key":"10.1016\/j.prp.2024.155589_bib61","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.xphs.2021.03.004","article-title":"Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2","volume":"110","author":"Peele","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.prp.2024.155589_bib62","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.virusres.2014.10.008","article-title":"Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus","volume":"194","author":"Sevajol","year":"2014","journal-title":"Virus Res."},{"key":"10.1016\/j.prp.2024.155589_bib63","doi-asserted-by":"crossref","unstructured":"Chang Y.-C., Tung Y.-A., Lee K.-H., Chen T.-F., Hsiao Y.-C., Chang H.-C., et al. Potential therapeutic agents for COVID-19 based on the analysis of protease and RNA polymerase docking. 2020.","DOI":"10.20944\/preprints202002.0242.v1"},{"issue":"6492","key":"10.1016\/j.prp.2024.155589_bib64","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.prp.2024.155589_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","author":"Gao","year":"2020","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.prp.2024.155589_bib66","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1007\/s00018-014-1695-z","article-title":"Common and unique features of viral RNA-dependent polymerases","volume":"71","author":"te Velthuis","year":"2014","journal-title":"Cell. Mol. life Sci."},{"key":"10.1016\/j.prp.2024.155589_bib67","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","article-title":"Role of favipiravir in the treatment of COVID-19","volume":"102","author":"Joshi","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.prp.2024.155589_bib68","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s15010-020-01557-7","article-title":"Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence","volume":"49","author":"Lin","year":"2021","journal-title":"Infection"},{"issue":"11","key":"10.1016\/j.prp.2024.155589_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/jfbc.14367","article-title":"Evaluation of the active constituents of Nilavembu Kudineer for viral replication inhibition against SARS-CoV-2: An approach to targeting RNA-dependent RNA polymerase (RdRp)","volume":"46","author":"Kuriakose","year":"2022","journal-title":"J. Food Biochem."},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib70","article-title":"Drug targets for corona virus: A systematic review","volume":"52","author":"Avti","year":"2020","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.prp.2024.155589_bib71","doi-asserted-by":"crossref","unstructured":"Chandel V., Raj S., Rathi B., Kumar D. In Silico Identification of Potent COVID-19 Main Protease Inhibitors from FDA Approved Antiviral Compounds and Active Phytochemicals through Molecular Docking: A Drug Repurposing Approach. 2020.","DOI":"10.20944\/preprints202003.0349.v1"},{"issue":"6489","key":"10.1016\/j.prp.2024.155589_bib72","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.prp.2024.155589_bib73","first-page":"173","article-title":"Coronavirus main proteinase: target for antiviral drug therapy","author":"Anand","year":"2005","journal-title":"Corona Spec. Emphas. first Insights Concern. SARS: Springe"},{"issue":"19","key":"10.1016\/j.prp.2024.155589_bib74","doi-asserted-by":"crossref","first-page":"8866","DOI":"10.1080\/07391102.2021.1918256","article-title":"In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins","volume":"40","author":"Elmaaty","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.prp.2024.155589_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.130968","article-title":"3CLpro and PLpro affinity, a docking study to fight COVID19 based on 900 compounds from PubChem and literature. Are there new drugs to be found?","volume":"1245","author":"\u0160tekl\u00e1\u010d","year":"2021","journal-title":"J. Mol. Struct."},{"issue":"9","key":"10.1016\/j.prp.2024.155589_bib76","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.3390\/molecules27092723","article-title":"Drug repurposing for COVID-19: A review and a novel strategy to identify new targets and potential drug candidates","volume":"27","author":"Rodrigues","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.prp.2024.155589_bib77","doi-asserted-by":"crossref","DOI":"10.1111\/bph.15092","article-title":"Potential therapeutic targets and promising drugs for combating SARS-CoV-2","author":"Zhou","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.prp.2024.155589_bib78","article-title":"Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV","author":"Liu","year":"2020","journal-title":"Chembiochem"},{"issue":"2","key":"10.1016\/j.prp.2024.155589_bib79","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.joim.2020.02.005","article-title":"In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus","volume":"18","author":"Zhang","year":"2020","journal-title":"J. Integr. Med."},{"issue":"2","key":"10.1016\/j.prp.2024.155589_bib80","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/antibiotics11020220","article-title":"Oral nirmatrelvir\/ritonavir therapy for COVID-19: The dawn in the dark?","volume":"11","author":"Hung","year":"2022","journal-title":"Antibiotics"},{"issue":"5","key":"10.1016\/j.prp.2024.155589_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036521","article-title":"Mechanism of nucleic acid unwinding by SARS-CoV helicase","volume":"7","author":"Adedeji","year":"2012","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.prp.2024.155589_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.102980","article-title":"Biochemical analysis of SARS-CoV-2 Nsp13 helicase implicated in COVID-19 and factors that regulate its catalytic functions","volume":"299","author":"Sommers","year":"2023","journal-title":"J. Biol. Chem."},{"issue":"13","key":"10.1016\/j.prp.2024.155589_bib83","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1042\/BCJ20210201","article-title":"Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase","volume":"478","author":"Zeng","year":"2021","journal-title":"Biochem. J."},{"issue":"22","key":"10.1016\/j.prp.2024.155589_bib84","doi-asserted-by":"crossref","first-page":"12062","DOI":"10.1080\/07391102.2021.1970024","article-title":"Discovering potential inhibitors against SARS-CoV-2 by targeting Nsp13 Helicase","volume":"40","author":"Nandi","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib85","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj4526","article-title":"Toward wide-spectrum antivirals against coronaviruses: Molecular characterization of SARS-CoV-2 NSP13 helicase inhibitors","volume":"8","author":"Perez-Lemus","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.prp.2024.155589_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105389","article-title":"Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro","volume":"206","author":"Lu","year":"2022","journal-title":"Antivir. Res."},{"issue":"21","key":"10.1016\/j.prp.2024.155589_bib87","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.3390\/molecules27217522","article-title":"Targeting SARS-CoV-2 Nsp13 helicase and assessment of druggability pockets: Identification of two potent inhibitors by a multi-site in silico drug repurposing approach","volume":"27","author":"Romeo","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.prp.2024.155589_bib88","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.phrs.2018.08.014","article-title":"Effect of statins on toll-like receptors: a new insight to pleiotropic effects","volume":"135","author":"Bahrami","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.prp.2024.155589_bib89","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13534","article-title":"The role of statins in the differentiation and function of bone cells","volume":"51","author":"Chamani","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.prp.2024.155589_bib90","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2016.07.897","article-title":"Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms","volume":"253","author":"Chru\u015bciel","year":"2016","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.prp.2024.155589_bib91","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jcsm.12654","article-title":"Effects of statins on mitochondrial pathways","volume":"12","author":"Mollazadeh","year":"2021","journal-title":"J. Cachex-.-., Sarcopenia Muscle"},{"key":"10.1016\/j.prp.2024.155589_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2021.101127","article-title":"A comprehensive review on the lipid and pleiotropic effects of pitavastatin","volume":"84","author":"Sahebkar","year":"2021","journal-title":"Prog. Lipid Res."},{"issue":"3","key":"10.1016\/j.prp.2024.155589_bib93","first-page":"546","article-title":"Association between statin use and plasma d-dimer levels: a systematic review and meta-analysis of randomised controlled trials","volume":"114","author":"Sahebkar","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.prp.2024.155589_bib94","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.5114\/aoms.2020.100304","article-title":"Statins and C-reactive protein: in silico evidence on direct interaction","volume":"16","author":"Shakour","year":"2020","journal-title":"Arch. Med. Sci."},{"issue":"9","key":"10.1016\/j.prp.2024.155589_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2020.183340","article-title":"Pleiotropic effects of statins on brain cells","volume":"1862","author":"Sodero","year":"2020","journal-title":"Biochim Biophys. Acta Biomembr."},{"issue":"12","key":"10.1016\/j.prp.2024.155589_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165968","article-title":"Pleiotropic effects of statins: A focus on cancer","volume":"1866","author":"Ahmadi","year":"2020","journal-title":"Biochim Biophys. Acta Mol. Basis Dis."},{"issue":"7","key":"10.1016\/j.prp.2024.155589_bib97","doi-asserted-by":"crossref","first-page":"533","DOI":"10.5543\/tkda.2021.21211","article-title":"Pleiotropic effects of statins: New evidences","volume":"49","author":"Okyay","year":"2021","journal-title":"Turk. Kardiyol. Dern. Ars"},{"key":"10.1016\/j.prp.2024.155589_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.820260","article-title":"Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study","volume":"9","author":"Kouhpeikar","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.prp.2024.155589_bib99","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1901772","article-title":"Improved COVID-19 Outcomes following Statin Therapy: An Updated Systematic Review and Meta-analysis","volume":"2021","author":"Vahedian-Azimi","year":"2021","journal-title":"Biomed. Res Int"},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib100","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1038\/s41598-022-09845-y","article-title":"Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis","volume":"12","author":"Ghosh","year":"2022","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.prp.2024.155589_bib101","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28971","article-title":"Outpatient atorvastatin use and severe COVID-19 outcomes: A population-based study","volume":"95","author":"Visos-Varela","year":"2023","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib102","doi-asserted-by":"crossref","first-page":"48","DOI":"10.24191\/jsst.v1i1.14","article-title":"Predicting AAK1\/GAK dual-target inhibitor against SARS-CoV-2 viral entry into host cells: an in silico approach","volume":"1","author":"Wezen","year":"2021","journal-title":"J. Smart Sci. Technol."},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib103","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2010.06.003","article-title":"Trilogy of ACE2: A peptidase in the renin\u2013angiotensin system, a SARS receptor, and a partner for amino acid transporters","volume":"128","author":"Kuba","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.prp.2024.155589_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2020.04.037","article-title":"The pivotal link between ACE2 deficiency and SARS-CoV-2 infection","author":"Verdecchia","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.prp.2024.155589_bib105","first-page":"1","article-title":"The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor-and angiotensin II receptor blocker-based antihypertensive therapies\u2014reply","author":"Albini","year":"2020","journal-title":"Intern. Emerg. Med."},{"issue":"10","key":"10.1016\/j.prp.2024.155589_bib106","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.prp.2024.155589_bib107","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.prp.2024.155589_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-020-01291-4","article-title":"Outcomes in patients with COVID-19 infection taking ACEI\/ARB","volume":"22","author":"Rico-Mesa","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"issue":"4","key":"10.1016\/j.prp.2024.155589_bib109","first-page":"374","article-title":"Investigating the human protein-host protein interactome of SARS-CoV-2 infection in the small intestine","volume":"13","author":"Khodadoost","year":"2020","journal-title":"Gastroenterol. Hepatol. bed bench"},{"key":"10.1016\/j.prp.2024.155589_bib110","article-title":"Anti-Fungal Drug Anidulafungin Inhibits SARS-CoV-2 Spike-Induced Syncytia Formation by Targeting ACE2-Spike Protein Interaction","volume":"578","author":"Ahamad","year":"2022","journal-title":"Front. Genet."},{"issue":"2","key":"10.1016\/j.prp.2024.155589_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010343","article-title":"Diltiazem inhibits SARS-CoV-2 cell attachment and internalization and decreases the viral infection in mouse lung","volume":"18","author":"Wang","year":"2022","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib112","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41422-020-00450-0","article-title":"Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models","volume":"31","author":"Wang","year":"2021","journal-title":"Cell Res."},{"issue":"4","key":"10.1016\/j.prp.2024.155589_bib113","doi-asserted-by":"crossref","first-page":"209","DOI":"10.34172\/bi.2020.27","article-title":"Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial","volume":"10","author":"Ansarin","year":"2020","journal-title":"BioImpacts: BI"},{"key":"10.1016\/j.prp.2024.155589_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1013911","article-title":"Mechanism of N-0385 blocking SARS-CoV-2 to treat COVID-19 based on molecular docking and molecular dynamics","volume":"13","author":"Cao","year":"2022","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib115","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/s41467-021-21972-0","article-title":"Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection","volume":"12","author":"Wettstein","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.prp.2024.155589_bib117","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3390\/antibiotics10070824","article-title":"Strawberry and ginger silver nanoparticles as potential inhibitors for SARS-CoV-2 assisted by in silico modeling and metabolic profiling","volume":"10","author":"Al-Sanea","year":"2021","journal-title":"Antibiotics"},{"issue":"2","key":"10.1016\/j.prp.2024.155589_bib118","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1021\/acs.jmedchem.0c01467","article-title":"Recent developments in the use of kinase inhibitors for management of viral infections","volume":"65","author":"Raghuvanshi","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.prp.2024.155589_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.prp.2024.155589_bib120","first-page":"195","article-title":"Evaluation of activation and inflammatory activity of myeloid cells during pathogenic human coronavirus infection","author":"Channappanavar","year":"2020"},{"issue":"12","key":"10.1016\/j.prp.2024.155589_bib121","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1007\/s42399-020-00610-8","article-title":"Dexamethasone for the treatment of coronavirus disease (COVID-19): a review","volume":"2","author":"Ahmed","year":"2020","journal-title":"SN Compr. Clin. Med."},{"issue":"14","key":"10.1016\/j.prp.2024.155589_bib122","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.3390\/ijms22147405","article-title":"Mechanisms of action and efficacy of hyaluronic acid, corticosteroids and platelet-rich plasma in the treatment of temporomandibular joint osteoarthritis\u2014a systematic review","volume":"22","author":"Derwich","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"20","key":"10.1016\/j.prp.2024.155589_bib123","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.prp.2024.155589_bib124","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/thoraxjnl-2020-215266","article-title":"Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19","volume":"76","author":"Khan","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.prp.2024.155589_bib125","article-title":"Targeting TNF-\u03b1 for COVID-19: recent advanced and controversies","volume":"10","author":"Guo","year":"2022","journal-title":"Front. Public Health"},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib126","article-title":"Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF\u03b1-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure","volume":"5","author":"Hachem","year":"2021","journal-title":"J. Clin. Transl. Sci."},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib127","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/biof.1566","article-title":"Effects of curcumin on mitochondria in neurodegenerative diseases","volume":"46","author":"Bagheri","year":"2020","journal-title":"Biofactors"},{"issue":"2","key":"10.1016\/j.prp.2024.155589_bib128","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00394-019-01916-7","article-title":"Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial","volume":"59","author":"Cicero","year":"2020","journal-title":"Eur. J. Nutr."},{"issue":"5","key":"10.1016\/j.prp.2024.155589_bib129","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1002\/jcp.27362","article-title":"Curcumin nanofibers for the purpose of wound healing","volume":"234","author":"Fereydouni","year":"2019","journal-title":"J. Cell Physiol."},{"issue":"6","key":"10.1016\/j.prp.2024.155589_bib130","first-page":"1192","article-title":"Analgesic efficacy and safety of curcuminoids in clinical practice: A systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Sahebkar","year":"2016","journal-title":"Pain Med"},{"issue":"10","key":"10.1016\/j.prp.2024.155589_bib131","doi-asserted-by":"crossref","first-page":"6530","DOI":"10.1002\/jcp.26620","article-title":"The versatile role of curcumin in cancer prevention and treatment: A focus on PI3K\/AKT pathway","volume":"233","author":"Hamzehzadeh","year":"2018","journal-title":"J. Cell Physiol."},{"issue":"4","key":"10.1016\/j.prp.2024.155589_bib132","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ptr.7737","article-title":"Curcumin-piperine co-supplementation and human health: A comprehensive review of preclinical and clinical studies","volume":"37","author":"Heidari","year":"2023","journal-title":"Phytother. Res"},{"issue":"10","key":"10.1016\/j.prp.2024.155589_bib133","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1002\/jcp.26538","article-title":"Phytosomal curcumin inhibits tumor growth in colitis-associated colorectal cancer","volume":"233","author":"Marjaneh","year":"2018","journal-title":"J. Cell Physiol."},{"issue":"2","key":"10.1016\/j.prp.2024.155589_bib134","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/jcp.27096","article-title":"Evidence of curcumin and curcumin analogue effects in skin diseases: A narrative review","volume":"234","author":"Panahi","year":"2019","journal-title":"J. Cell Physiol."},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/19390211.2014.952865","article-title":"Effects of curcuminoids-piperine combination on systemic oxidative stress, clinical symptoms and quality of life in subjects with chronic pulmonary complications due to sulfur mustard: A randomized controlled trial","volume":"13","author":"Panahi","year":"2016","journal-title":"J. Diet. Suppl."},{"key":"10.1016\/j.prp.2024.155589_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104353","article-title":"Targeting regulatory T cells by curcumin: A potential for cancer immunotherapy","volume":"147","author":"Shafabakhsh","year":"2019","journal-title":"Pharm. Res"},{"issue":"2","key":"10.1016\/j.prp.2024.155589_bib137","doi-asserted-by":"crossref","DOI":"10.3390\/nu14020256","article-title":"Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials","volume":"14","author":"Vahedian-Azimi","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.prp.2024.155589_bib138","doi-asserted-by":"crossref","DOI":"10.1089\/jmf.2022.K.0029","article-title":"Potential Mechanisms of Perillae folium Against COVID-19: A Network Pharmacology Approach","author":"Chen","year":"2023","journal-title":"J. Med. Food"},{"key":"10.1016\/j.prp.2024.155589_bib139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40001-021-00626-3","article-title":"Potential therapeutic options for COVID-19: an update on current evidence","volume":"27","author":"Niknam","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.prp.2024.155589_bib140","unstructured":"Romagnoli S., Peris A., de Gaudio A.R., Geppetti P. SARS-CoV-2 and COVID-19: between pathophysiology complexity and therapeutic uncertainty. Physiological Reviews. 2020."},{"issue":"5","key":"10.1016\/j.prp.2024.155589_bib141","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: a clinical\u2013therapeutic staging proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J. Heart Lung Transplant."},{"issue":"4","key":"10.1016\/j.prp.2024.155589_bib142","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1152\/physrev.00020.2020","article-title":"SARS-CoV-2 and COVID-19: from the bench to the bedside","volume":"100","author":"Romagnoli","year":"2020","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.prp.2024.155589_bib143","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3390\/vaccines11020332","article-title":"A clinical insight on new discovered molecules and repurposed drugs for the treatment of COVID-19","volume":"11","author":"Banerjee","year":"2023","journal-title":"Vaccines"},{"issue":"6","key":"10.1016\/j.prp.2024.155589_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103579","article-title":"COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease","volume":"28","author":"Kronenberger","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jocn.16150","article-title":"Symptoms and management of long COVID: A scoping review","volume":"33","author":"Cha","year":"2024","journal-title":"J. Clin. Nurs."},{"issue":"1","key":"10.1016\/j.prp.2024.155589_bib146","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s15010-023-02154-0","article-title":"Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review","volume":"52","author":"Fern\u00e1ndez-de-Las-Pe\u00f1as","year":"2024","journal-title":"Infection"},{"issue":"3","key":"10.1016\/j.prp.2024.155589_bib147","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S2213-2600(23)00414-9","article-title":"The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia","volume":"12","author":"Catal\u00e0","year":"2024","journal-title":"Lancet Respir. Med."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824005004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824005004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T03:50:33Z","timestamp":1732333833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824005004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":147,"alternative-id":["S0344033824005004"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155589","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular targets in SARS-CoV-2 infection: An update on repurposed drug candidates","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"155589"}}